Such a Deal, Late-Phase
Executive SummaryThe cliché is that late-stage deals are necessarily expensive. Genentech is showing they don't have to be, lowering its cost of access to drugs by weighting most of its payments towards equity and milestones--and buying the drugs others pass over as too risky.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.